Serious adverse effects · people with chronic gout
Allopurinol 100‐300 mg daily showed no clear difference in serious adverse effects compared with febuxostat 80 mg daily (moderate certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Allopurinol 100‐300 mg daily showed no clear difference in acute gout attacks compared with febuxostat 80 mg daily (low certainty).
1 finding from 1 review
Proportion achieving target serum urate · people with chronic gout
Allopurinol 100‐300 mg daily may leads to lower proportion achieving target serum urate compared with febuxostat 80 mg daily (low certainty).
1 finding from 1 review
sUA reduction · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Total adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Tophus regression · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Acute gout attacks · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Acute gout attacks · people with chronic gout
Benzbromarone showed no clear difference in acute gout attacks compared with allopurinol (low certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Probenecid showed no clear difference in acute gout attacks compared with allopurinol (low certainty).
1 finding from 1 review
Serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events ‐ not reported · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Total adverse events ‐ not reported · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Pain reduction ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Serum urate normalisation ‐ not reported · people with chronic gout
Benzbromarone showed no clear difference in serum urate normalisation compared with allopurinol (moderate certainty).
1 finding from 1 review
Function ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Tophus regression ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Benzbromarone showed no clear difference in withdrawal due to adverse events compared with allopurinol (low certainty).
1 finding from 1 review